 Connection
Manojkumar Bupathi to Retrospective Studies
This is a "connection" page, showing publications Manojkumar Bupathi has written about Retrospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.115 |
|
|
|
-
Bupathi M, Hays JL, Chen JL. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. PLoS One. 2017; 12(11):e0188116.
Score: 0.038
-
Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol. 2016 Apr; 33(4):37.
Score: 0.034
-
Shah NJ, Sura S, Shinde R, Dai W, Wentworth C, Conkling P, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study. Urol Oncol. 2026 Apr; 44(4):110979.
Score: 0.017
-
Sura S, Bupathi M, Morris V, Conkling P, Todoroff K, Bhanegaonkar A, Ike C. Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study. Curr Oncol. 2025 Mar 24; 32(4).
Score: 0.016
-
Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, Duggan MC, Bupathi M, Brock GN, Millis SZ, Shakya R, Timmers CD, Wakely PE, Pollock RE, Chen JL. Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. Oncologist. 2019 07; 24(7):989-996.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|